The Latest in Lymphoma & Plasma Cell Disorders

Cancer patients’ complaints about care

September 25, 2017

EC expands approval of obinutuzumab in FL

September 23, 2017

Team creates guidelines on CAR T-cell-related toxicity

September 20, 2017

Trials of atezolizumab placed on partial hold

September 19, 2017

Application for pegfilgrastim biosimilar withdrawn

September 17, 2017

FDA approves drug to treat relapsed FL

September 15, 2017

Immune status linked to outcomes of CAR T-cell therapy

September 15, 2017

Survey reveals lack of specialized care for AYAs with cancer

September 15, 2017

Report details progress, obstacles in cancer research and care

September 14, 2017

Biosimilar deemed equivalent to reference drug in FL

September 12, 2017

Study: Many cancer patients don’t understand clinical trials

September 11, 2017

CCSs have higher burden of chronic conditions

September 9, 2017

FDA places full, partial holds on durvalumab trials

September 8, 2017

FDA grants orphan designation to product for CMV

September 6, 2017

FDA grants orphan designation to product for GVHD

September 6, 2017